FDA/CDC

FDA grants breakthrough therapy designation for severe aplastic anemia drug

Publish date: January 4, 2018
By
Lori Laubach

 

The Food and Drug Administration has granted breakthrough therapy designation to eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia (SAA).

FDA icon
The breakthrough therapy designation – which provides expedited review for drugs for serious or life-threatening conditions – is based on results from a phase 1-2 study conducted by researchers at the National Heart, Lung, and Blood Institute. In all, 52% of newly treated patients with SAA achieved a complete response at 6 months when treated with eltrombopag at the start of and concurrently with standard immunosuppressive treatment, according to an analysis of the data conducted by Novartis, which sponsors the drug.

Eltrombopag already is approved as a second-line therapy in patients with refractory SAA and is approved for adults and children with refractory chronic immune thrombocytopenia (ITP).

“Promacta is a promising medicine that, if approved for first-line use in severe aplastic anemia, may redefine the standard of care for patients with this rare and serious bone marrow condition,” Samit Hirawat, MD, head of Novartis Oncology Global Drug Development, said in a statement.

Recommended Reading

Stable response in sickle cell disease patient treated with gene therapy
MDedge Pediatrics
In sickle cell disease, osteomyelitis is a tough call
MDedge Pediatrics
FDA advisory committee supports L-glutamine for SCD
MDedge Pediatrics
FDA approves first new drug for sickle cell in nearly 20 years
MDedge Pediatrics
Allele-matching in cord blood transplant yields better survival
MDedge Pediatrics
L-glutamine to prevent sickle cell complications featured in FDA podcast
MDedge Pediatrics
Guidelines cut acute chest syndrome hospital returns in pediatric sickle cell
MDedge Pediatrics
Emerging sickle cell agents target new pathways
MDedge Pediatrics
Clinic eases pediatric-adult transition in sickle cell disease
MDedge Pediatrics
FDA approves hydroxyurea for pediatric patients with sickle cell anemia
MDedge Pediatrics